Induced lesions by nonsteroidal anti-inflammatory drugs;Lesoes induzidas por AINEs no sistema digestorio

Revista Brasileira de Medicina

Volumn 57, Issue 8, 2000, Pages 882-900

  Zaterka, Schlioma ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Gastrointestinal disorders; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; METRONIDAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

AGE DISTRIBUTION; ANEMIA; ANOREXIA; CLINICAL FEATURE; COLITIS; CROHN DISEASE; DIVERTICULITIS; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENTEROCOLITIS; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOALBUMINEMIA; INTESTINE PERFORATION; MUSCLE WEAKNESS; PEPTIC ULCER; REVIEW; RISK FACTOR;

EID: 0033822709     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebro vascular ischemic events. Lancet 1991; 338:1345-1349.
2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294.
3. Thun MJ, Namboodiri MM, Health CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
4. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and non-steroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114:441-447.
5. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992; 42:447-449.
6. Breitner JCS. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47:401-411.
7. Vane JR, Botting RM. Mechanism of action of non-steroidal anti-inflammatory drugs. Am J Med 1998; 104: 2S-8S.
8. Stone E. An account of the success of the bark of the willow in the cure of agues. Phil Trans Roy Soc 1763:53:195-200 in Vane & Botting- Mechanism of action of non-steroidal anti-inflammatory drugs. Am J Med 1998; 104:2S-8S.
9. Stone E. An account of the success of the bark of the willow in the cure of agues. Phil Trans Roy Soc 1763:53:195-200 in Vane & Botting- Mechanism of action of non-steroidal anti-inflammatory drugs. Am J Med 1998; 104:2S-8S.
10. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990; 21(suppl IV): 12-23.
11. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26:33-67.
12. Collier HOJ. Aspirin. Sci Am 1963; 209:97-108.
13. Collier HOJ. A pharmacological analysis of aspirin. Adv Pharmacol Chemother. 1969; 7:333-405.
14. Spector WG, Willoughby DA. Anti-inflammatory effects of salicylate in the rat. In: Dixon A STJ, Martin BK, Smith MJH, Wood PHN, eds., Salicylates: An International Symposium. Boston: Little Brown, 1963: 141-147.
15. Piper PJ, Vane JR. The release of prostaglandins during anaphylaxis in guinea-pig isolated lungs. In: Mantegazza P, Horton EW, eds. Protaglandins, Peptides and Amines. London, New York: Academic Press, 1969:15-19.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231:232-235.
17. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971; 241:235-237.
18. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolishes prostaglandin release from spleen. Nature 1971; 231:237-239.
19. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J Lipid Med 1993 ;6:275-286.
20. Weissmann G. Aspirin. Sci Am 1991;264:84-90.
21. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240:410-411.
22. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(3A):2S-8S.
23. Whittle BJR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980; 284:271-273.
24. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostgandin G/H synthase:a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 1992; 25:249-265.
25. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340:1888-1899.
26. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Nat Acad Sci USA. 1994; 91:12013-12017.
27. Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acutepost-surgical pain model. J Invest Med 1996; 44:293 A.
28. Hubbard R, Geis GS, Woods E, et al.. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum 1998; 41(suppl 9): S196. Abst 982.
29. Churchill L, Graham A, Shin C-K, et al. Selective inhibition of human cyclooxigenase-2 by meloxicam. Inflammopharmacology 1996; 4:125-135.
30. Böttcher I, Schweiser A, Glatt M, Werner H. A sulphonamido-indanone CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastrointestinal ulcerogenicity in rats. Drugs Exp Clin Res 1987; 13:237-245.
31. Critchlow J, Magee D, Ito S et al. Requirement for restitution of the surface epithelium of frog stomach after mucosal injury. Gastroenterology 1985; 88:237-249.
32. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leucocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109:1173-1180.
33. Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Effect of nonsteroidal ant-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266:G657-G664.
34. Santucci L, Florucci S, Brunori PM et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumor necrosis factor alpha. Gut 1994; 35:909-915.
35. Appleyard CB, McCafferty DM, Tigley AW et al. Tumor necrosis factor mediation of NSAIDs-induced gastric damage: role of leukocite adherence. Am J Physiol 1996; 270:G42-G48.
36. Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal micricirculation. Gastropenterology 1987; 93:810-817.
37. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Phisiol 1990; 259:G462-G467.
38. Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Phisiol 1993; 265:G993-G998.
39. Rainsford KD. The effect of 5-lipooxigenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by non-steroidal anti-inflammatory drugs in mice. Agents Action 1987; 21:316-319.
40. Vaanaren PM, Keenan CM, Grisham MB, Wallace JL. A pharmacological investigation of the role of leukotrienes in the pathologenesis of experimental NSAID-gastropathy. Inflammation 1992; 16:227-240.
41. Soll AH Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) damage the gastric and duodenal mucosa. pp307-309. In Soll AH, moderator. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307-319.
42. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy; the second hundred years. Gastroenterology 1997; 112:1000-1016.
43. Douthwaite AH, Lintott SAM. Gastroscopic observation on the effect of aspirin and certain other substances on the stomach. Lancet 1938; 2; 1222-1225.
44. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic ulcer disease: a report from the Boston Collaborative Drug Surveillance Program. N Engl J Med 1974; 290:1159-1162.
45. Sun DC, Roth SH, Mitchell CS, Englund DW. Upper gastrointestinal disease in reumathoid arthritis. Am J Dig Dis 1974; 19:405-410.
46. Grahan DY, Smith JL. Aspirin and the stomach. Ann Int Med 1986;104:390-398.
47. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983; 28:1-6.
48. O'Laughlin JC, Hoftieser JW, Ivey KJ. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours and 2 weeks after administration. Scand J Gastroenterol 1981; 67(suppl); 211-214.
49. Croft DN, Wood PHN. Gastric mucosa and susceptibility to occult gastrointestinal bleeding caused by aspirin. Br Med J 1967; 1:137-141.
50. Mehta S, Dasarathy S, Tandon RK et al. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. Am J Gastroenterolog 1992; 87: 996-1000.
51. Weiss A, Pitman ER, Graham DY. Aspirin and gastric bleeding: gastroscopic observations, with review of the literature. Am J Med 1961; 31:266-278.
52. Muir A, Cossar IA. Aspirin and ulcer. Br Med J 1955; 2:7-12.
53. Weinstein WM. Differentiation of nonsteroidal anti-inflammatory drug-associated and "ordinary" peptic ulcers, pp 309-311. In Soll AH, moderator. Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114: 307-319.
54. Kurata JH, Elashoff JD, Grossman MI. Inadequacy of the literature on the relashionship between drugs, ulcers and gastrointestinal bleeding. Gastroenterology 1982; 82:373-86.
55. Kurata JH. An assessment of nonsteroidal anti-inflammatory drugs as a risk factor in ulcer disease, pp.311-315. In SOLL AH, moderator. Non-steroidal anti-inflammatory drugs and pepticulcer disease. Ann Intern Med 1991; 114-:307-319.
56. Somerville K, Faulkner G, Langman M. Non-sterodal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1:462-4.
57. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 1990; 12:260-6.
58. Silverstein FE, Grahan DY, Senior JR e col. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nosteroids anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern Med 1995; 123:241-9.
59. Paulus HE, Government affairs. FDA Arthritis Advisory Committee meeting: risks of agranulocytosis /aplastic anemia, flank pain, and adverse gastrointestinal effects with the use of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1987; 30:593-5.
60. Singh G, Ramey R. NSAID Induced Gastrointestinal Complications: The ARAMIS Perspective-1997. J Rheumatol 1998; 25(Suppl. 51):8-16.
61. Polisson R. Non-steroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med 1996; 100 (Suppl 2A): 31S-36S.
62. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerations. Gut 1987; 28:527-32.
63. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38:5-18.
64. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of non-steroidal anti-inflammatory drugs treatment in rheumatoid arthritis: A prospective observation coorte study. Arch Intern Med 1996; 156:1530-1536.
65. Fries JF, Williams CA, Bloch DA, Michel BA. NSAID-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91:213-222.
66. Griffin MR, Piper JM, Daugherty JR et al. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Inten Med 1991; 114:257-263.
67. Gabriel SE, Jaakkimainen L, Bombardier C. Risk fornserious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787-796.
68. Griffin, Piper, Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterolog 1995; 90:206-210.
69. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104(3 A):23S-29S.
70. Singh G. Recent considerations in non-inflammatory drug gastropathy. Am J Med 1998; 105:31S-38S.
71. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-1078.
72. Henry D, Lim LL-Y, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-1566.
73. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772.
74. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual non-steroisl anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in Saskatchewan:a nested case-control study. Pharmacoepidemiol Drug Safety 1994; 3:S63.
75. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nosteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-740.
76. Shorr RI, Ray WA, Daugherty JR et al. Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665-1670.
77. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomized controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: Help NSAIDs study. Lancet 1998; 352:1016-1021.
78. Blanchi Porro G, Parente F, Imbesi V et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut 1996; 39:22-26.
79. Marfertheiner P, Labenz J. Does Helicobacter pylori status affect non-steroidal anti-inflammatory drug-associated gastroduodenal pathology? Am J Med 1998; 104:353-408.
80. Bjarnason I, Fehily B, Smethurst P et al. The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in man. Gut 1991; 32:275-277.
81. Bjarnasos I, Zanelli G, Smith T et al. Nonsteroidal anti-inflammatory drug induced inflammation in humans. Gastroenterology 1987; 93:480-489.
82. Morris AJ, Wasson LA, MacKenzie JF. Small bowell enteroscopy in undignosed gastrointestinal bood loss. Gut 1992; 33:887-889.
83. Bjarnason I, Hayllar J, Andrew J et al. Side effects of non-steroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832-1847.
84. Bjarnason I, Zanelli G, Prouse P et al. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet 1987;2:711-714.
85. Bjarnason I, Price AB, zanelli G et al. Clinicopathological features of NSAID induced small intestinal strictures. Gastroenterology 1988;94:1070-1074.
86. Hall RI, Petty AH, Cobden I, Lendrum R. Enteritis and colitis associated with mefenamic acid. Br Med J 1983; 287;1182.
87. Edwards AL, Heagerty AM, Bing RF. Enteritis and colitis asociated with mefenamic acid. Br Med J 1983;287:1627.
88. Isaacs PET, Sladen GE, Filpie I. Mefenamic acid enteropathy. J Clin Pathol 1987; 40:121-127.
89. Bridges AJ, Marshall JB, Diaz-Arias AA. Acute eosinophilic colitis and hipersensitivity reaction associated with naproxen therapy. Am J Med 1990; 89:526-527.
90. Gentric A, Pennec YL. Diclofenac-induced pseudomembraneous colitis. Lancet 1992;340: 126-127
91. Tanaka M, Mazzoleni G, Ridell RH. Nonsteroidal anti-inflammatory drugs as a possible cause of collagenous colitis. Gastroenterology 1991; 101:A 485 (abstr.).
92. Mielants H, Veys EM, Cuvelier C, et al. Ileocolonoscopy findings in seronegative spondyloarthropathies. Br J Reumatol 1988; 27(suppl 2):95-105.
93. Berry H, Seinson D, Jones H, Hamilton EBD. Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. Ann Rheum Dis 1978; 37:370-372.
94. Lanthier P, Detry R, Debongnie JC et al. Solitary rectal lesions due to suppositories confining acetylsalicilic acid and paracetamol. Gastroenterol Clin biol 1987; 11;250-253.
95. Wilson RG, Smith NA, Macintyre IMC. Complications of diverticular disease and nonsteroidal anti-inflammatory drugs: A prospective study. Br J Surg 1990; 77:1103-1104.
96. Kaufman HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Inn Med 1987; 107:513-516.
97. Yeomans ND. New data on healing of non steroidal anti-inflammatory drug-associated ulcers and erosions. Am J Med 1998; 104(3 A):56S-61S.
98. Hawkey CJ. Progress in prophylaxis agains non-steroidal anti-inflammatory drug-associated ulcers and erosions. Am J Med 1998; 104(3 A): 67S-74S.
99. Bjarnason I, Hayllar J, Smethurst P et al. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 1992; 33:1204-1208.
100. Gibson T. Non-steroidal anti-inflammatory drugs-another look. Br J Rheumatol 1989; 27:87-90.
101. Barrier CH, Hirschowitz BI. Current controversies in reumathology. Controversies in detection and management of non-steroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthitis Reum 1989; 32:926-929.
102. WHO Drug Information 1999; 13:96.
103. Singh G, Ramey DR, Triadafilopoulos G. Early experience with selective COX-2 inhibitors: safety profile in over 340.000 patient years. Abstract 1352, American College of Rheumatology Annual Meeting, 1999.
104. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of Celecoxib in rheumatoid arthritis. A randomized trial. Jama 1999; 282: 1921-1928.
105. Langman MJ, Jensen DM, Watson DJ, et alk. Adverse upper gastrointestinal effects of Rofecoxib compared with NSAIDs. Jama 1999; 282: 1929-1933.
106. Goldstein JL, Agrawal N, Silverstein F, et al. Effect of Celecoxib (Cel) versus placebo (PBO) or NSAIDs in healing of gastric and duodenal erosions in arthritis patients: analysis of controlled endoscopic studies. Am J Gastroenterol 1999; 94 (9): 126 (abstr.).
107. Steinbach G, Lynch PM, Phillips R, et al. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am J Gastroenterol 1999; 94(9):440 (abstr.).